MedTrace Logo

U-LABA/ICS Effects on Exercise Performance, Formoterol

NCT06105671 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-08-13

No results posted yet for this study

Summary

The purpose of the project is to investigate exercise performance in well-trained individuals in a crossover design following varying degrees of bronchodilation/constriction intervention using current standard procedures.

Conditions

  • Exercise Performance

Interventions

DRUG

Symbicort

Participants are administered 54 μg Formoterol and 1920 μg Budesonide

DRUG

Formoterol

Participants are administered 54 μg Formoterol from an inhaler device

DRUG

Formoterol

Participants are administered 120 μg Formoterol in a capsule, which is taken orally

DRUG

Placebo

Participants are administered placebo

DRUG

Mannitol

Participants are administered 600 mg Bronchitol

Sponsors & Collaborators

  • Morten Hostrup, PhD

    lead OTHER

Principal Investigators

  • Morten Hostrup, PhD · University of Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-05
Primary Completion
2024-07-04
Completion
2024-07-04

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06105671 on ClinicalTrials.gov